Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

LEVODROPROPIZINE IMPURITY B CRS (50 MG)

LEVODROPROPIZINE IMPURITY B CRS (50 MG)

92-54-6

DISCOVER
LYNESTRENOL FOR PEAK IDENTIFICATION CRS (20 MG)

LYNESTRENOL FOR PEAK IDENTIFICATION CRS (20 MG)

52-76-6

DISCOVER
MELOXICAM IMPURITY A CRS (15 MG)

MELOXICAM IMPURITY A CRS (15 MG)

NA

DISCOVER
MELOXICAM IMPURITY B CRS (5 MG)

MELOXICAM IMPURITY B CRS (5 MG)

7305-71-7

DISCOVER
MELOXICAM IMPURITY C CRS (10 MG)

MELOXICAM IMPURITY C CRS (10 MG)

1262333-25-4

DISCOVER
BENAZEPRIL FOR SYSTEM SUITABILITY CRS (0.016 MG)

BENAZEPRIL FOR SYSTEM SUITABILITY CRS (0.016 MG)

86541-74-4

DISCOVER
MELOXICAM IMPURITY D CRS (20 MG)

MELOXICAM IMPURITY D CRS (20 MG)

NA

DISCOVER
MESITYL OXIDE CRS (110 MG)

MESITYL OXIDE CRS (110 MG)

141-79-7

DISCOVER
MIANSERIN IMPURITY B CRS (10 MG)

MIANSERIN IMPURITY B CRS (10 MG)

NA

DISCOVER
OMEPRAZOLE FOR PEAK IDENTIFICATION CRS (10 MG)

OMEPRAZOLE FOR PEAK IDENTIFICATION CRS (10 MG)

73590-58-6

DISCOVER
OMEPRAZOLE MAGNESIUM CRS (10 MG)

OMEPRAZOLE MAGNESIUM CRS (10 MG)

95382-33-5

DISCOVER
OXYMETAZOLINE IMPURITY A CRS (15 MG)

OXYMETAZOLINE IMPURITY A CRS (15 MG)

NA

DISCOVER